Lucy Dorrell

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Therapeutic immunization for the control of HIV-1: where are we now?
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Int J STD AIDS 17:436-41; quiz 442. 2006
  2. pmc Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    J Virol 80:4705-16. 2006
  3. ncbi request reprint Therapeutic immunization strategies for the control of HIV-1
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Expert Rev Vaccines 4:513-20. 2005
  4. ncbi request reprint Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses
    Beatrice O Ondondo
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 36:2585-94. 2006
  5. ncbi request reprint Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Vaccine 25:3277-83. 2007
  6. ncbi request reprint Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy
    Hongbing Yang
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    J Immunol 179:597-606. 2007
  7. ncbi request reprint Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK
    AIDS 19:1321-3. 2005
  8. pmc Design and pre-clinical evaluation of a universal HIV-1 vaccine
    Sven Létourneau
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, United Kingdom
    PLoS ONE 2:e984. 2007
  9. ncbi request reprint Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART
    Rebecca Sutherland
    MRC Human Immunology Unit, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    AIDS 20:821-9. 2006
  10. ncbi request reprint Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Inese Cebere
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Vaccine 24:417-25. 2006

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Therapeutic immunization for the control of HIV-1: where are we now?
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Int J STD AIDS 17:436-41; quiz 442. 2006
    ..Augmentation of HIV-specific immunity by therapeutic vaccination is a possible alternative to continuous HAART. In this review, progress in the development of therapeutic immunization strategies is discussed...
  2. pmc Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    J Virol 80:4705-16. 2006
    ..These data suggest that immunization with MVA.HIVA is a feasible strategy to enhance potentially protective T-cell responses in individuals with chronic HIV-1 infection...
  3. ncbi request reprint Therapeutic immunization strategies for the control of HIV-1
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Expert Rev Vaccines 4:513-20. 2005
    ..The status of therapeutic vaccines that are currently undergoing preclinical and clinical evaluation is reviewed...
  4. ncbi request reprint Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses
    Beatrice O Ondondo
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 36:2585-94. 2006
    ..These findings indicate that functional virus-specific T helper cells can be boosted by vaccination in chronic HIV-1 infection. Further evaluation of their role in viraemia control is warranted...
  5. ncbi request reprint Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Vaccine 25:3277-83. 2007
    ..These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies...
  6. ncbi request reprint Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy
    Hongbing Yang
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    J Immunol 179:597-606. 2007
    ..The potential therapeutic benefit of this vaccination approach warrants further investigation...
  7. ncbi request reprint Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK
    AIDS 19:1321-3. 2005
    ..We evaluated the safety and immunogenicity, in HIV-1-infected individuals under HAART suppression, of a DNA vaccine, pTHr.HIVA...
  8. pmc Design and pre-clinical evaluation of a universal HIV-1 vaccine
    Sven Létourneau
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, United Kingdom
    PLoS ONE 2:e984. 2007
    ..One of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which could limit the value of any HIV-1 vaccine candidate currently under test...
  9. ncbi request reprint Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART
    Rebecca Sutherland
    MRC Human Immunology Unit, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
    AIDS 20:821-9. 2006
    ..To determine whether long-term HAART in chronic HIV-1 infection restores fully functional Mycobacterium tuberculosis (MTB)-specific CD4 T-cell responses...
  10. ncbi request reprint Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Inese Cebere
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Vaccine 24:417-25. 2006
    ..HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies...
  11. ncbi request reprint Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction
    Tomas Hanke
    Weatherall Institute of Molecular Medicine, MRC Human Immunology Unit, University of Oxford, The John Radcliffe, Oxford OX3 9DS, UK
    J Gen Virol 88:1-12. 2007
    ..Thus, whilst the search is on for ways to enhance T-cell priming, MVA is a useful boosting vector for human subunit genetic vaccines...
  12. ncbi request reprint Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia
    Beatrice O Ondondo
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 38:3549-60. 2008
    ..This suggests that other factors may control viral replication in HIV-2 infection...
  13. ncbi request reprint Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption
    Hongbing Yang
    MRC Human Immunology Unit and Oxford NIHR Biomedical Research Centre, Weatherall Institute of Molecular Medicine John Radcliffe Hospital, Oxford OX3 9DS, UK
    AIDS 23:2226-30. 2009
    ..Surprisingly, IL-10 blockade augmented HIV-specific T cell proliferative responses in HAART-suppressed patients but had no effect once virological control was lost. Modulation of IL-10 might enhance vaccine-induced immune responses...
  14. doi request reprint Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection
    Hongbing Yang
    Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
    J Immunol Methods 391:174-8. 2013
    ..The protocol described here is rapid and cost-effective compared with ELISA and thus could be a useful component of immune monitoring of HIV-1 vaccines and interventions to reduce viral reservoirs...
  15. doi request reprint Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects
    Sarah Howles
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Vaccine 28:7306-12. 2010
    ..In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens...
  16. ncbi request reprint CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype
    Geraldine M A Gillespie
    MRC Human Immunology Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 35:1445-53. 2005
    ..Immune control of HIV-2 does not appear to be related to the frequency of perforin-expressing virus-specific CD8(+) T cells...
  17. ncbi request reprint A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
    Matilu Mwau
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford OX3 9DS, UK
    J Gen Virol 85:911-9. 2004
    ..These results are very encouraging and justify further vaccine development...
  18. pmc T cell cross-reactivity and conformational changes during TCR engagement
    Jean K Lee
    Human Immunology Unit, Medical Research Council, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, England, UK
    J Exp Med 200:1455-66. 2004
    ..These findings have implications for the rational design of vaccines targeting viruses with unstable genomes...
  19. pmc Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled
    Nilu Goonetilleke
    Centre for Clinical Vaccinology and Tropical Medicine and MRC Human Immunology Unit, University of Oxford, Oxford OX3 7LJ, United Kingdom
    J Virol 80:4717-28. 2006
    ..These data demonstrate that prime-boost vaccination with recombinant DNA and MVA vectors can induce multifunctional HIV-1-specific T cells in the majority of vaccinees...
  20. pmc Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
    Nicola Borthwick
    1 The Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Oxford, UK 2 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, UK
    Mol Ther 22:464-75. 2014
    ..These results provide proof of concept for using a vaccine to target T cells at conserved epitopes, showing that these T cells can control HIV-1 replication in vitro. ..
  21. ncbi request reprint Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection
    A Ross Lopes
    Institute of Hepatology, University College London, London, United Kingdom
    J Immunol 171:307-16. 2003
    ..Furthermore, they have implications for HIV vaccine development, demonstrating an association between a polyclonal, virus-specific CD8(+) T cell response and an enhanced capacity to tolerate substitutions within T cell epitopes...